Sunday - July 13, 2025

LOGIN  |  REGISTER
Assertio
Compass Therapeutics

Zai Lab Announces Participation in Investor Conferences in June 2025

May 30, 2025 | Last Trade: US$32.73 1.35 -3.96

SHANGHAI & CAMBRIDGE, Mass. / May 30, 2025 / Business Wire / Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in June 2025:

Jefferies Global Healthcare Conference
Fireside Chat: Wednesday, June 4, 2025, 10:30 a.m. EST
Webcast Link: https://wsw.com/webcast/jeff319/zlab/1845848
Location: New York, NY

Goldman Sachs 46th Annual Healthcare Conference
Time: Monday, June 9, 2025
Location: Miami, FL

Scotiabank Third Annual Healthcare Canadian Investor Day
Time: Tuesday, June 17, 2025
Location: Toronto, Canada

A live webcast of the fireside chat will be available on the Investor Relations page of Zai Lab’s website at ir.zailaboratory.com/webcasts-presentations and archived replay will be available for up to 90 days following the completion of the event.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.X.com/ZaiLab_Global.

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page